

5th World Congress on

Diabetes & Metabolism

November 03-05, 2014 Embassy Suites Las Vegas, USA



Premanidhi Panda

Dr. Panda Diabetes Centre, India

Pioglitazone vs Voglibose on glycemic control study in type II diabetes in Indian population

Introduction: Diabetes mellitus, often simply referred to as diabetes—is a group of metabolic diseases in which a person has high blood sugar, either because the body does not produce enough insulin, or because cells do not respond to the insulin that is produced.

Type 2 diabetes mellitus consists of an array of dysfunctions characterized by hyperglycemia and resulting from the combination of resistance to insulin action, inadequate insulin secretion, and excessive or inappropriate glucagons secretion. It is with both Micro vascular & macro vascular complications. Type II diabetes is a progressive disease. It requires two to three drug combinations produce good effects and less side effects. Therefore these two drugs taken into consideration like Pioglitazone and Voglibose. It shows good glycemic control FBS, 2hr PPBS & HbA1C and Cholesterol and Triglyceride. Particularly study has been seen whose Blood sugar was not controlled by Glimiperide and Metformin.

Intent: Intent of the study done By Author from 2012 February to July 2012 over a period of 6 Months over 200 Cases Type –II Diabetes shows tremendous result in reduction of blood sugar, Maintenance of Blood sugar very stable as compared to with Pioglitazone or voglibose who are under Uncontrolled blood sugar with Glimiperide and Metformin. It shows good glycemic control Constant maintenance of HBA1C 5.8 to 6.5 range. Reduction in Lipid Profile Serum Cholesterol, Serum Triglyceride, LDL& VLDL.

Method:—Two randomised group within the age group 30-70 Years of Type II either sex given Pioglitazone and Voglibose with the FBS > 130mg/dl, HbA1C between 7-10 selected at random. All the parameters like FBS, 2hr PPBS, HbA1c, Lipid profile cholesterol, Triglyceride, LDL & VLDL observed time to time. It was observed within 6 months FBS, 2hr PPBS, HbA1c, Cholesterol, TG, LDL&VLDL was greatly effected with Pioglitazone than Voglibose. Non of the patient complaint anything with pioglitazone except weight gain. With Voglibose few patient shows Flatulence, abdominal distension, Increase in LFT.

Conclusion:—In my study shows Pioglitazone has got more effective drug than Voglibose Without any side effect. Better control of FBS, 2hr PPBS, Lipid Profile. In my study shows Pioglitazone has got minimal sideeffects than voglibose.

****I HAVE GOT >40, 000 Diabetes Patients. More than 20, 000 Patients are under Pioglitazone since 2009. . Even I had given my view to Govt of India not to banned Pioglitazone.

Biography

Premanidhi panda has completed his MBBS at the age of 24 years from Berhampur University, India and postdoctoral studies from Utkal university School of Medicine. He is the director of Dr Panda diabetes institute, India, a premier Diabetes hospital cum research centre, India. He has worked in Tisco hospital, india, benghazi medical(libya), medwin hospital with repute. He has been awarded as "India's best doctor award:-2013(Diabetes)" by medgate today survey.

drpanda@sify.com